Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Fludarabine, Bendamustine, and Rituximab (FBR) Non-Myeloablative Allogeneic Conditioning for Patients With Lymphoid Malignancies

Next Previous
Search
Trial Profile

Fludarabine, Bendamustine, and Rituximab (FBR) Non-Myeloablative Allogeneic Conditioning for Patients With Lymphoid Malignancies

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 09 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bendamustine (Primary) ; Filgrastim; Fludarabine; Methotrexate; Rituximab; Tacrolimus; Tacrolimus
  • Indications B-cell lymphoma; Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Follicular lymphoma; Graft-versus-host disease; Mantle-cell lymphoma
  • Focus Adverse reactions

    • Most Recent Events

    • 08 Dec 2020 Results (n=26) assessing safety and efficacy of Inotuzumab Ozogamicin when added to standard nonmyeloablative alloSCT conditioning regimen and also compared patients data who received BFR+alloSCT without Inotuzumab Ozogamicin in prior studies presented at the 62nd Annual Meeting and Exposition of the American Society of Hematology
    • 30 May 2019 Status changed from active, no longer recruiting to completed.
    • 04 Dec 2018 Results presented at the 60th Annual Meeting and Exposition of the American Society of Hematology.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top